Tag
Piramal Pharma Limited
9 articles
Piramal Pharma reported a challenging fiscal year 2026, with flat Q4 revenue of ₹2,752 crore and a 3% decline in full-year revenue to ₹8,869 crore, attributed to CDMO destocking and softer ex-US anesthesia sales. The company incurred a net loss of ₹326 crore for the year, impacted by an exceptional impairment charge. Despite margin contraction to 13% from 17% the prior year, management anticipates growth acceleration across all businesses in fiscal 2027, citing a recovery in biopharma funding and the recent Kenalog® acquisition. Regulatory updates include a successful FDA inspection of the Digwal facility with no observations, while the Sellersville facility is addressing three Voluntary Action Indicated observations following a recent inspection.
Piramal Pharma Announces June 2026 Investor Meetings
Piramal Pharma discloses schedule of analyst and institutional investor meetings for May-June 2026 pursuant to SEBI LODR Regulation 30(6).
Five meetings scheduled with major financial institutions inc
Piramal Pharma Digwal Facility US FDA Inspection Closed
Piramal Pharma received an Establishment Inspection Report from the US FDA for its Digwal, Telangana manufacturing facility.
The US FDA inspection, initiated in February 2026, has been successfully cl
Piramal Pharma US FDA Inspection Gets 3 VAI Observations
US FDA conducted a GMP inspection at Piramal Pharma's Sellersville facility from May 4-8, 2026.
The inspection concluded with a Form-483 containing three observations classified as Voluntary Action In
Piramal Pharma Schedules Trinity India 2026 Investor Meet
Piramal Pharma intimates schedule for analyst and institutional investor meetings under SEBI LODR Regulations.
Company to participate in 360 ONE Capital's Trinity India 2026 conference in Mumbai on Ma
Piramal Pharma Q4 FY26 Conference Call Transcript Available
Piramal Pharma Limited has made the transcript of its Q4 FY26 results conference call available on its website.
The call was held on 29th April 2026 to discuss audited standalone and consolidated fina
Piramal Pharma Q4 FY26 Earnings Call Recording Available
Piramal Pharma Limited intimated availability of its Q4 FY26 earnings call audio recording on the company website.
The conference call was held on 29th April 2026 to discuss audited standalone and con
Piramal Pharma Q4 FY26 Earnings Call Recording Available
Piramal Pharma Limited makes the audio recording of its Q4 and FY26 earnings conference call available on its website.
The call was held on 29th April 2026 to discuss audited standalone and consolidat
Piramal Pharma Q4 Revenue Flat, FY26 PAT at -₹326Cr
Piramal Pharma reported flat Q4 revenue of ₹2,752Cr, with a full-year decline of 3% to ₹8,869Cr, impacted by CDMO destocking and soft ex-US anesthesia sales.
The company recorded a full-year net loss
Piramal Pharma Q4 Net Profit Dips 5.6% YoY
• Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting FY net profit of ₹700.01 crore.
• Reappointed four directors including Executive Ch